Goldman Sachs Maintains Buy on Arcus Biosciences, Raises Price Target to $34

Benzinga Newsdesk www.benzinga.com Positive 75.5%

Neg 0% Neu 0% Pos 75.5%

Goldman Sachs analyst Richard Law maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $30 to $34.